This report was recently updated on January 15 2025 with the latest and most recent
market numbers
Global Age-related Macular Degeneration (AMD) Drugs Market Size, Trends & Analysis - Forecasts to 2029 By Product (Lucentis, Eylea & Eylea HD, Vabysmo, Syfovre, and Others), By Molecules (Ranibizumab, Aflibercept, Faricimab, Pegcetoplan, and Others), By Type of AMD (Wet AMD and Dry AMD), By End User (Hospitals, Specialty Centers, and Long-term Care Facilities), and By Region (North America, Asia Pacific, Central and South America, Europe, and Middle East and Africa), Competitive Landscape, Company Market Share Analysis, and End User Analysis
The global age-related macular degeneration (AMD) drugs market is estimated to exhibit a CAGR of 11.1% from 2024 to 2029.
The primary factors propelling the market growth are the increasing prevalence of age-related macular degeneration and the growing demand for advanced therapies. As the aging population grows, the number of individuals affected by AMD continues to rise, leading to a higher demand for effective treatment options. AMD is a progressive condition that can severely impact vision, prompting patients and healthcare providers to seek advanced therapies to manage its symptoms and slow disease progression. This demand has spurred significant developments in treatment options, particularly anti-VEGF drugs, which have become the standard of care for AMD. Additionally, greater awareness about AMD and the benefits of early intervention have further increased the adoption of these drugs. The rising prevalence of AMD is, therefore, directly driving the market's growth by emphasizing the need for effective and accessible treatment solutions.
Rising awareness about early diagnosis and treatment options for macular degeneration along with the increasing R&D investments in novel AMD therapies are expected to support the market growth. To address unmet needs in AMD care, pharmaceutical and biotechnology companies are concentrating on creating novel therapeutic options. This includes advancements in gene therapies, stem cell-based treatments, and next-generation anti-VEGF drugs, which aim to improve efficacy, reduce treatment burden, and address the limitations of existing therapies. The pursuit of personalized medicine has further encouraged research into biomarkers and precision-targeted drugs, enhancing patient outcomes. Governments and private organizations are also offering funding and incentives to accelerate drug development, fostering innovation in the AMD therapeutic space. These investments have led to a robust pipeline of potential treatments, including long-acting formulations and combination therapies.
Technological advancements in drug delivery systems for ocular diseases coupled with the rising adoption of minimally invasive treatment methods for AMD propel market growth. Innovative delivery technologies, such as sustained-release implants, intravitreal injections with extended dosing intervals, and nanoparticle-based systems, are transforming the way AMD treatments are administered. These advancements aim to enhance the efficacy of drugs, reduce the frequency of treatments, and improve patient compliance by minimizing the burden of frequent clinic visits. For example, long-acting formulations allow for a controlled release of medication over time, reducing the need for repeated injections, which is a significant concern for AMD patients. Additionally, emerging technologies like biodegradable implants and micro-needles are improving precision and comfort during drug administration. These developments not only improve treatment results but also draw large sums of money from pharmaceutical companies.
Gene therapy represents a breakthrough opportunity for addressing AMD at its root cause, with ongoing research focusing on single-dose solutions and durable treatments to transform patient care and reduce the need for repeated interventions. Additionally, the growing demand for long-acting drug formulations provides an opportunity to innovate and deliver treatments that reduce the frequency of administration, improving patient adherence and overall treatment effectiveness.
However, the high cost of AMD therapies and the lack of effective dry AMD treatments can impede market growth.
-drugs-market.png)
The Eylea & Eylea HD segment is expected to hold the largest share of the market over the forecast period. Eylea is approved for multiple retinal conditions, including AMD, diabetic macular edema, and retinal vein occlusion. This wide range of indications enhances its market share, as it is widely prescribed for various conditions alongside AMD, making it a versatile solution.
The Vabysmo segment is expected to be the fastest-growing segment in the market from 2024 to 2029. Vabysmo’s innovative dual-pathway mechanism targeting both VEGF-A and Ang-2 offers improved efficacy in treating AMD. This unique approach provides superior disease control compared to traditional single-target drugs, making it highly appealing to healthcare providers and driving its rapid adoption in the AMD drugs market.
The aflibercept segment is expected to hold the largest share of the market over the forecast period. With longer treatment intervals and prolonged efficacy, Aflibercept lessens the need for frequent injections. This convenience significantly enhances patient adherence and satisfaction, solidifying its widespread adoption in AMD therapy.
The ranibizumab segment is anticipated to be the fastest-growing segment in the market from 2024 to 2029. Ranibizumab offers shorter and more frequent injection cycles compared to some competitors. This may enhance its attractiveness to patients and healthcare providers, leading to increased market adoption, thus driving its rapid growth in the AMD segment.
The wet AMD segment is expected to hold the largest share of the market over the forecast period. Due to the rapid progression of wet AMD, which can cause significant vision loss in a short period, there is a higher demand for effective treatments. This urgency for intervention drives the larger share of the market toward therapies targeting wet AMD.
The dry AMD segment is expected to be the fastest-growing segment in the market from 2024 to 2029. The dry AMD segment has seen a surge in investigational drugs, with promising therapies targeting key disease mechanisms, such as inflammation and cellular regeneration. This segment for AMD drugs is expanding quickly due to the expected approval and commercialization of these medications.
The hospitals segment is expected to hold the largest share of the market over the forecast period. Hospitals offer access to the latest treatments, including anti-VEGF injections and novel therapies for AMD. As these treatments require medical supervision and proper infrastructure, hospitals are preferred by patients, ensuring they hold the largest share of the AMD drug market.
The specialty centers segment is anticipated to be the fastest-growing segment in the market from 2024 to 2029. Specialty centers frequently provide individualized treatment programs that consider each patient's particular requirements. This individualized approach, combined with specialized expertise, increases patient satisfaction and drives growth in the specialty centers segment of the AMD drugs market.
-drugs-market.png)
North America is expected to be the largest region in the global market. North America, particularly the United States, has a significant aging population, which leads to a higher prevalence of age-related macular degeneration (AMD). The growing number of elderly individuals in this region directly contributes to the demand for AMD treatments, making it the largest market.
Asia Pacific is anticipated to witness rapid growth during the forecast period. Asia Pacific has made significant advancements in healthcare infrastructure, particularly in urban areas. The growing availability of specialized eye care centers, advanced diagnostic equipment, and treatments for AMD is boosting the region’s market growth, making it a key player in the global AMD drugs market.
Regeneron Pharmaceuticals Inc., Bayer AG, F. Hoffmann-La Roche AG, Novartis AG, Apellis Pharmaceuticals, Inc., Coherus BioSciences, Inc., Astellas Pharma Inc., Biogen, STADA Arzneimittel AG, and Formycon AG among others, are some of the key players in the global age-related macular degeneration (AMD) drugs market.
Please note: This is not an exhaustive list of companies profiled in the report.
In July 2024, the U.S. Food and Drug Administration (FDA) approved F. Hoffmann-La Roche Ltd.'s Vabysmo (faricimab) 6.0 mg single-dose prefilled syringe (PFS) for use in treating patients with nAMD. These prefilled syringes provide a convenient way to take drugs.
In July 2024, to treat neovascular or "wet" age-related macular degeneration (AMD), Genentech (Roche) reintroduced Susvimo (100 mg/mL ranibizumab injection) for intravitreal usage via ocular implant in the United States.
1 STRATEGIC INSIGHTS ON NEW REVENUE POCKETS
1.1 Strategic Opportunity & Attractiveness Analysis
1.1.1 Hot Revenue Pockets
1.1.2 Market Attractiveness Score
1.1.3 Revenue Impacting Opportunity
1.1.4 High Growing Region/Country
1.1.5 Competitor Analysis
1.1.6 Consumer Analysis
1.2 Global Market Estimates' View
1.3 Strategic Insights across Business Functions
1.3.1 For Chief Executive Officers
1.3.2 For Chief Marketing Officers
1.3.3 For Chief Strategy Officers
1.4 Evaluate the Potential of your Existing Business Lines vs. New Lines to Enter Into
2 TECHNOLOGICAL TRENDS
2.1 Technological Adoption Rate
2.2 Current Trend Impact Analysis
2.3 Future Trend Impact Analysis
3 GLOBAL MARKET OUTLOOK
3.1 Market Pyramid Analysis
3.1.1 Introduction
3.1.2 Adjacent Market Opportunities
3.1.3 Ancillary Market Opportunities
3.2 Demand Side Analysis
3.2.1 Market Drivers: Impact Analysis
3.2.2 Market Restraints: Impact Analysis
3.2.3 Market Opportunities: Impact Analysis
3.2.4 Market Challenges: Impact Analysis
3.3 Supply Side Analysis
3.3.1 Porter’s Five Forces Analysis
3.3.1.1 Threat of New Entrants
3.3.1.2 Threat of New Substitutes
3.3.1.3 Bargaining Power of Suppliers
3.3.1.4 Bargaining Power of Buyers
3.3.1.5 Intensity of Competitive Rivalry
3.3.2 SWOT Analysis; By Factor (Political & Legal, Economic, and Technological)
3.3.2.1 Political Landscape
3.3.2.2 Economic Landscape
3.3.2.3 Social Landscape
3.3.2.4 Technology Landscape
3.3.3 Value Chain Analysis
3.3.4 Trend Analysis
3.3.5 Gap Analysis
3.3.6 Cost Analysis
4 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT
4.1 Introduction
4.2 Age-related Macular Degeneration (AMD) Drugs Market: Product Scope Key Takeaways
4.3 Revenue Growth Analysis, 2023 & 2029
4.4 Lucentis
4.4.1 Lucentis Market Estimates and Forecast, 2021-2029 (USD Billion)
4.5 Eylea & Eylea HD
4.5.1 Eylea & Eylea HD Market Estimates and Forecast, 2021-2029 (USD Billion)
4.6 Vabysmo
4.6.1 Vabysmo Market Estimates and Forecast, 2021-2029 (USD Billion)
4.7 Syfovre
4.7.1 Syfovre Market Estimates and Forecast, 2021-2029 (USD Billion)
4.8 Others
4.8.1 Others Market Estimates and Forecast, 2021-2029 (USD Billion)
5 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULES
5.1 Introduction
5.2 Age-related Macular Degeneration (AMD) Drugs Market: Molecules Scope Key Takeaways
5.3 Revenue Growth Analysis, 2023 & 2029
5.4 Ranibizumab
5.4.1 Ranibizumab Market Estimates and Forecast, 2021-2029 (USD Billion)
5.5 Aflibercept
5.5.1 Aflibercept Market Estimates and Forecast, 2021-2029 (USD Billion)
5.6 Faricimab
5.6.1 Faricimab Market Estimates and Forecast, 2021-2029 (USD Billion)
5.7 Pegcetoplan
5.7.1 Pegcetoplan Market Estimates and Forecast, 2021-2029 (USD Billion)
5.8 Others
5.8.1 Others Market Estimates and Forecast, 2021-2029 (USD Billion)
6 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD
6.1 Introduction
6.2 Age-related Macular Degeneration (AMD) Drugs Market: Type of AMD Scope Key Takeaways
6.3 Revenue Growth Analysis, 2023 & 2029
6.4 Wet AMD
6.4.1 Wet AMD Market Estimates and Forecast, 2021-2029 (USD Billion)
6.5 Dry AMD
6.5.1 Dry AMD Market Estimates and Forecast, 2021-2029 (USD Billion)
7 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER
7.1 Introduction
7.2 Age-related Macular Degeneration (AMD) Drugs Market: End User Scope Key Takeaways
7.3 Revenue Growth Analysis, 2023 & 2029
7.4 Specialty Centers
7.4.1 Specialty Centers Market Estimates and Forecast, 2021-2029 (USD Billion)
7.5 Long-term Care Facilities
7.5.1 Long-term Care Facilities Market Estimates and Forecast, 2021-2029 (USD Billion)
7.6 Hospitals
7.6.1 Hospitals Market Estimates and Forecast, 2021-2029 (USD Billion)
8 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY REGION
8.1 Introduction
8.2 North America Age-related Macular Degeneration (AMD) Drugs Market Estimates and Forecast, 2021-2029 (USD Billion)
8.2.1 By Product
8.2.2 By Molecules
8.2.3 By Type of AMD
8.2.4 By End User
8.2.5 By Country
8.2.5.1 U.S. Age-related Macular Degeneration (AMD) Drugs Market Estimates and Forecast, 2021-2029 (USD Billion)
8.2.5.1.1 By Product
8.2.5.1.2 By Molecules
8.2.5.1.3 By Type of AMD
8.2.5.1.4 By End User
8.2.5.2 Canada Age-related Macular Degeneration (AMD) Drugs Market Estimates and Forecast, 2021-2029 (USD Billion)
8.2.5.2.1 By Product
8.2.5.2.2 By Molecules
8.2.5.2.3 By Type of AMD
8.2.5.2.4 By End User
8.2.5.3 Mexico Age-related Macular Degeneration (AMD) Drugs Market Estimates and Forecast, 2021-2029 (USD Billion)
8.2.5.3.1 By Product
8.2.5.3.2 By Molecules
8.2.5.3.3 By Type of AMD
8.2.5.3.4 By End User
8.3 Europe Age-related Macular Degeneration (AMD) Drugs Market Estimates and Forecast, 2021-2029 (USD Billion)
8.3.1 By Product
8.3.2 By Molecules
8.3.3 By Type of AMD
8.3.4 By End User
8.3.5 By Country
8.3.5.1 Germany Age-related Macular Degeneration (AMD) Drugs Market Estimates and Forecast, 2021-2029 (USD Billion)
8.3.5.1.1 By Product
8.3.5.1.2 By Molecules
8.3.5.1.3 By Type of AMD
8.3.5.1.4 By End User
8.3.5.2 U.K. Presered Flowers Market Estimates and Forecast, 2021-2029 (USD Billion)
8.3.5.2.1 By Product
8.3.5.2.2 By Molecules
8.3.5.2.3 By Type of AMD
8.3.5.2.4 By End User
8.3.5.3 France Age-related Macular Degeneration (AMD) Drugs Market Estimates and Forecast, 2021-2029 (USD Billion)
8.3.5.3.1 By Product
8.3.5.3.2 By Molecules
8.3.5.3.3 By Type of AMD
8.3.5.3.4 By End User
8.3.5.4 Italy Age-related Macular Degeneration (AMD) Drugs Market Estimates and Forecast, 2021-2029 (USD Billion)
8.3.5.4.1 By Product
8.3.5.4.2 By Molecules
8.3.5.4.3 By Type of AMD
8.3.5.4.4 By End User
8.3.5.5 Spain Age-related Macular Degeneration (AMD) Drugs Market Estimates and Forecast, 2021-2029 (USD Billion)
8.3.5.5.1 By Product
8.3.5.5.2 By Molecules
8.3.5.5.3 By Type of AMD
8.3.5.5.4 By End User
8.3.5.6 Netherlands Age-related Macular Degeneration (AMD) Drugs Market Estimates and Forecast, 2021-2029 (USD Billion)
8.3.5.6.1 By Product
8.3.5.6.2 By Molecules
8.3.5.6.3 By Type of AMD
8.3.5.6.4 By End User
8.3.5.7 Rest of Europe Age-related Macular Degeneration (AMD) Drugs Market Estimates and Forecast, 2021-2029 (USD Billion)
8.3.5.7.1 By Product
8.3.5.7.2 By Molecules
8.3.5.7.3 By Type of AMD
8.3.5.7.4 By End User
8.4 Asia Pacific Age-related Macular Degeneration (AMD) Drugs Market Estimates and Forecast, 2021-2029 (USD Billion)
8.4.1 By Product
8.4.2 By Molecules
8.4.3 By Type of AMD
8.4.4 By End User
8.4.5 By Country
8.4.5.1 China Age-related Macular Degeneration (AMD) Drugs Market Estimates and Forecast, 2021-2029 (USD Billion)
8.4.5.1.1 By Product
8.4.5.1.2 By Molecules
8.4.5.1.3 By Type of AMD
8.4.5.1.4 By End User
8.4.5.2 Japan Age-related Macular Degeneration (AMD) Drugs Market Estimates and Forecast, 2021-2029 (USD Billion)
8.4.5.2.1 By Product
8.4.5.2.2 By Molecules
8.4.5.2.3 By Type of AMD
8.4.5.2.4 By End User
8.4.5.3 India Age-related Macular Degeneration (AMD) Drugs Market Estimates and Forecast, 2021-2029 (USD Billion)
8.4.5.3.1 By Product
8.4.5.3.2 By Molecules
8.4.5.3.3 By Type of AMD
8.4.5.3.4 By End User
8.4.5.4 South Korea Age-related Macular Degeneration (AMD) Drugs Market Estimates and Forecast, 2021-2029 (USD Billion)
8.4.5.4.1 By Product
8.4.5.4.2 By Molecules
8.4.5.4.3 By Type of AMD
8.4.5.4.4 By End User
8.4.5.5 Singapore Age-related Macular Degeneration (AMD) Drugs Market Estimates and Forecast, 2021-2029 (USD Billion)
8.4.5.5.1 By Product
8.4.5.5.2 By Molecules
8.4.5.5.3 By Type of AMD
8.4.5.5.4 By End User
8.4.5.6 Malaysia Age-related Macular Degeneration (AMD) Drugs Market Estimates and Forecast, 2021-2029 (USD Billion)
8.4.5.6.1 By Product
8.4.5.6.2 By Molecules
8.4.5.6.3 By Type of AMD
8.4.5.6.4 By End User
8.4.5.7 Thailand Age-related Macular Degeneration (AMD) Drugs Market Estimates and Forecast, 2021-2029 (USD Billion)
8.4.5.7.1 By Product
8.4.5.7.2 By Molecules
8.4.5.7.3 By Type of AMD
8.4.5.7.4 By End User
8.4.5.8 Indonesia Age-related Macular Degeneration (AMD) Drugs Market Estimates and Forecast, 2021-2029 (USD Billion)
8.4.5.8.1 By Product
8.4.5.8.2 By Molecules
8.4.5.8.3 By Type of AMD
8.4.5.8.4 By End User
8.4.5.9 Vietnam Age-related Macular Degeneration (AMD) Drugs Market Estimates and Forecast, 2021-2029 (USD Billion)
8.4.5.9.1 By Product
8.4.5.9.2 By Molecules
8.4.5.9.3 By Type of AMD
8.4.5.9.4 By End User
8.4.5.10 Taiwan Age-related Macular Degeneration (AMD) Drugs Market Estimates and Forecast, 2021-2029 (USD Billion)
8.4.5.10.1 By Product
8.4.5.10.2 By Molecules
8.4.5.10.3 By Type of AMD
8.4.5.10.4 By End User
8.4.5.11 Rest of Asia Pacific Age-related Macular Degeneration (AMD) Drugs Market Estimates and Forecast, 2021-2029 (USD Billion)
8.4.5.11.1 By Product
8.4.5.11.2 By Molecules
8.4.5.11.3 By Type of AMD
8.4.5.11.4 By End User
8.5 Middle East and Africa Age-related Macular Degeneration (AMD) Drugs Market Estimates and Forecast, 2021-2029 (USD Billion)
8.5.1 By Product
8.5.2 By Molecules
8.5.3 By Type of AMD
8.5.4 By End User
8.5.5 By Country
8.5.5.1 Saudi Arabia Age-related Macular Degeneration (AMD) Drugs Market Estimates and Forecast, 2021-2029 (USD Billion)
8.5.5.1.1 By Product
8.5.5.1.2 By Molecules
8.5.5.1.3 By Type of AMD
8.5.5.1.4 By End User
8.5.5.2 U.A.E. Age-related Macular Degeneration (AMD) Drugs Market Estimates and Forecast, 2021-2029 (USD Billion)
8.5.5.2.1 By Product
8.5.5.2.2 By Molecules
8.5.5.2.3 By Type of AMD
8.5.5.2.4 By End User
8.5.5.3 Israel Age-related Macular Degeneration (AMD) Drugs Market Estimates and Forecast, 2021-2029 (USD Billion)
8.5.4.3.1 By Product
8.5.4.3.2 By Molecules
8.5.4.3.3 By Type of AMD
8.5.5.3.4 By End User
8.5.5.4 South Africa Age-related Macular Degeneration (AMD) Drugs Market Estimates and Forecast, 2021-2029 (USD Billion)
8.5.5.4.1 By Product
8.5.5.4.2 By Molecules
8.5.5.4.3 By Type of AMD
8.5.5.4.4 By End User
8.5.5.5 Rest of Middle East and Africa Age-related Macular Degeneration (AMD) Drugs Market Estimates and Forecast, 2021-2029 (USD Billion)
8.5.5.5.1 By Product
8.5.5.5.2 By Molecules
8.5.5.5.2 By Type of AMD
8.5.5.5.4 By End User
8.6 Central & South America Age-related Macular Degeneration (AMD) Drugs Market Estimates and Forecast, 2021-2029 (USD Billion)
8.6.1 By Product
8.6.2 By Molecules
8.6.3 By Type of AMD
8.6.4 By End User
8.6.5 By Country
8.6.5.1 Brazil Age-related Macular Degeneration (AMD) Drugs Market Estimates and Forecast, 2021-2029 (USD Billion)
8.6.5.1.1 By Product
8.6.5.1.2 By Molecules
8.6.5.1.3 By Type of AMD
8.6.5.1.4 By End User
8.6.5.2 Argentina Age-related Macular Degeneration (AMD) Drugs Market Estimates and Forecast, 2021-2029 (USD Billion)
8.6.5.2.1 By Product
8.6.5.2.2 By Molecules
8.6.5.2.3 By Type of AMD
8.6.5.2.4 By End User
8.6.5.3 Chile Age-related Macular Degeneration (AMD) Drugs Market Estimates and Forecast, 2021-2029 (USD Billion)
8.6.5.3.1 By Product
8.6.5.3.2 By Molecules
8.6.5.3.3 By Type of AMD
8.6.5.5.4 By End User
8.6.5.4 Rest of Central & South America Age-related Macular Degeneration (AMD) Drugs Market Estimates and Forecast, 2021-2029 (USD Billion)
8.6.5.4.1 By Product
8.6.5.4.2 By Molecules
8.6.5.4.3 By Type of AMD
8.6.5.4.4 By End User
9 COMPETITIVE LANDCAPE
9.1 Company Market Share Analysis
9.2 Four Quadrant Positioning Matrix
9.2.1 Market Leaders
9.2.2 Market Visionaries
9.2.3 Market Challengers
9.2.4 Niche Market Players
9.3 Vendor Landscape
9.3.1 North America
9.3.2 Europe
9.3.3 Asia Pacific
9.3.4 Rest of the World
9.4 Company Profiles
9.4.1 Regeneron Pharmaceuticals Inc.
9.4.1.1 Business Description & Financial Analysis
9.4.1.2 SWOT Analysis
9.4.1.3 Products & Services Offered
9.4.1.4 Strategic Alliances between Business Partners
9.4.2 Bayer AG
9.4.2.1 Business Description & Financial Analysis
9.4.2.2 SWOT Analysis
9.4.2.3 Products & Services Offered
9.4.2.4 Strategic Alliances between Business Partners
9.4.3 F. Hoffmann-La Roche AG
9.4.3.1 Business Description & Financial Analysis
9.4.3.2 SWOT Analysis
9.4.3.3 Products & Services Offered
9.4.3.4 Strategic Alliances between Business Partners
9.4.4 Novartis AG
9.4.4.1 Business Description & Financial Analysis
9.4.4.2 SWOT Analysis
9.4.4.3 Products & Services Offered
9.4.4.4 Strategic Alliances between Business Partners
9.4.5 Apellis Pharmaceuticals, Inc.
9.4.5.1 Business Description & Financial Analysis
9.4.5.2 SWOT Analysis
9.4.5.3 Products & Services Offered
9.4.5.4 Strategic Alliances between Business Partners
9.4.6 COHERUS BIOSCIENCES, INC.
9.4.6.1 Business Description & Financial Analysis
9.4.6.2 SWOT Analysis
9.4.6.3 Products & Services Offered
9.4.6.4 Strategic Alliances between Business Partners
9.4.7 Astellas Pharma Inc.
9.4.7.1 Business Description & Financial Analysis
9.4.7.2 SWOT Analysis
9.4.7.3 Products & Services Offered
9.4.8.4 Strategic Alliances between Business Partners
9.4.8 Biogen
9.4.8.1 Business Description & Financial Analysis
9.4.8.2 SWOT Analysis
9.4.8.3 Products & Services Offered
9.4.8.4 Strategic Alliances between Business Partners
9.4.9 STADA Arzneimittel AG
9.4.9.1 Business Description & Financial Analysis
9.4.9.2 SWOT Analysis
9.4.9.3 Products & Services Offered
9.4.9.4 Strategic Alliances between Business Partners
9.4.10 Formycon AG
9.4.10.1 Business Description & Financial Analysis
9.4.10.2 SWOT Analysis
9.4.10.3 Products & Services Offered
9.4.10.4 Strategic Alliances between Business Partners
9.4.11 Other Companies
9.4.11.1 Business Description & Financial Analysis
9.4.11.2 SWOT Analysis
9.4.11.3 Products & Services Offered
9.4.11.4 Strategic Alliances between Business Partners
10 RESEARCH METHODOLOGY
10.1 Market Introduction
10.1.1 Market Definition
10.1.2 Market Scope & Segmentation
10.2 Information Procurement
10.2.1 Secondary Research
10.2.1.1 Purchased Databases
10.2.1.2 GMEs Internal Data Repository
10.2.1.3 Secondary Resources & Third Party Perspectives
10.2.1.4 Company Information Sources
10.2.2 Primary Research
10.2.2.1 Various Types of Respondents for Primary Interviews
10.2.2.2 Number of Interviews Conducted throughout the Research Process
10.2.2.3 Primary Stakeholders
10.2.2.4 Discussion Guide for Primary Participants
10.2.3 Expert Panels
10.2.3.1 Expert Panels Across 30+ Industry
10.2.4 Paid Local Experts
10.2.4.1 Paid Local Experts Across 30+ Industry Across each Region
10.3 Market Estimation
10.3.1 Top-Down Approach
10.3.1.1 Macro-Economic Indicators Considered
10.3.1.2 Micro-Economic Indicators Considered
10.3.2 Bottom Up Approach
10.3.2.1 Company Share Analysis Approach
10.3.2.2 Estimation of Potential Product Sales
10.4 Data Triangulation
10.4.1 Data Collection
10.4.2 Time Series, Cross Sectional & Panel Data Analysis
10.4.3 Cluster Analysis
10.5 Analysis and Output
10.5.1 Inhouse AI Based Real Time Analytics Tool
10.5.2 Output From Desk & Primary Research
10.6 Research Assumptions & Limitations
10.7.1 Research Assumptions
10.7.2 Research Limitations
LIST OF TABLES
1 Global Age-related Macular Degeneration (AMD) Drugs Market, By Product, 2021-2029 (USD Billion)
2 Lucentis Market, By Region, 2021-2029 (USD Billion)
3 Eylea & Eylea HD Market, By Region, 2021-2029 (USD Billion)
4 Vabysmo Market, By Region, 2021-2029 (USD Billion)
5 Syfovre Market, By Region, 2021-2029 (USD Billion)
6 Others Market, By Region, 2021-2029 (USD Billion)
7 Global Age-related Macular Degeneration (AMD) Drugs Market, By Molecules, 2021-2029 (USD Billion)
8 Ranibizumab Market, By Region, 2021-2029 (USD Billion)
9 Aflibercept Market, By Region, 2021-2029 (USD Billion)
10 Faricimab Market, By Region, 2021-2029 (USD Billion)
11 Pegcetoplan Market, By Region, 2021-2029 (USD Billion)
12 Others Market, By Region, 2021-2029 (USD Billion)
13 Global Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD, 2021-2029 (USD Billion)
14 Wet AMD Market, By Region, 2021-2029 (USD Billion)
15 Dry AMD Market, By Region, 2021-2029 (USD Billion)
16 Global Age-related Macular Degeneration (AMD) Drugs Market, By END USER, 2021-2029 (USD Billion)
17 Specialty Centers Market, By Region, 2021-2029 (USD Billion)
18 Long-term Care Facilities Market, By Region, 2021-2029 (USD Billion)
19 Hospitals Market, By Region, 2021-2029 (USD Billion)
20 Regional Analysis, 2021-2029 (USD Billion)
21 North America Age-related Macular Degeneration (AMD) Drugs Market, By Product, 2021-2029 (USD Billion)
22 North America Age-related Macular Degeneration (AMD) Drugs Market, By Molecules, 2021-2029 (USD Billion)
23 North America Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD, 2021-2029 (USD Billion)
24 North America Age-related Macular Degeneration (AMD) Drugs Market, By End User, 2021-2029 (USD Billion)
25 North America Age-related Macular Degeneration (AMD) Drugs Market, By Country, 2021-2029 (USD Billion)
26 U.S Age-related Macular Degeneration (AMD) Drugs Market, By Product, 2021-2029 (USD Billion)
27 U.S Age-related Macular Degeneration (AMD) Drugs Market, By Molecules, 2021-2029 (USD Billion)
28 U.S Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD, 2021-2029 (USD Billion)
29 U.S Age-related Macular Degeneration (AMD) Drugs Market, By End User, 2021-2029 (USD Billion)
30 Canada Age-related Macular Degeneration (AMD) Drugs Market, By Product, 2021-2029 (USD Billion)
31 Canada Age-related Macular Degeneration (AMD) Drugs Market, By Molecules, 2021-2029 (USD Billion)
32 Canada Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD, 2021-2029 (USD Billion)
33 CANADA Age-related Macular Degeneration (AMD) Drugs Market, By End User, 2021-2029 (USD Billion)
34 Mexico Age-related Macular Degeneration (AMD) Drugs Market, By Product, 2021-2029 (USD Billion)
35 Mexico Age-related Macular Degeneration (AMD) Drugs Market, By Molecules, 2021-2029 (USD Billion)
36 Mexico Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD, 2021-2029 (USD Billion)
37 mexico Age-related Macular Degeneration (AMD) Drugs Market, By End User, 2021-2029 (USD Billion)
38 Europe Age-related Macular Degeneration (AMD) Drugs Market, By Product, 2021-2029 (USD Billion)
39 Europe Age-related Macular Degeneration (AMD) Drugs Market, By Molecules, 2021-2029 (USD Billion)
40 Europe Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD, 2021-2029 (USD Billion)
41 europe Age-related Macular Degeneration (AMD) Drugs Market, By End User, 2021-2029 (USD Billion)
42 europe Age-related Macular Degeneration (AMD) Drugs Market, By COUNTRY, 2021-2029 (USD Billion)
43 Germany Age-related Macular Degeneration (AMD) Drugs Market, By Product, 2021-2029 (USD Billion)
44 Germany Age-related Macular Degeneration (AMD) Drugs Market, By Molecules, 2021-2029 (USD Billion)
45 Germany Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD, 2021-2029 (USD Billion)
46 germany Age-related Macular Degeneration (AMD) Drugs Market, By End User, 2021-2029 (USD Billion)
47 UK Age-related Macular Degeneration (AMD) Drugs Market, By Product, 2021-2029 (USD Billion)
48 UK Age-related Macular Degeneration (AMD) Drugs Market, By Molecules, 2021-2029 (USD Billion)
49 UK Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD, 2021-2029 (USD Billion)
50 U.k Age-related Macular Degeneration (AMD) Drugs Market, By End User, 2021-2029 (USD Billion)
51 France Age-related Macular Degeneration (AMD) Drugs Market, By Product, 2021-2029 (USD Billion)
52 France Age-related Macular Degeneration (AMD) Drugs Market, By Molecules, 2021-2029 (USD Billion)
53 France Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD, 2021-2029 (USD Billion)
54 France Age-related Macular Degeneration (AMD) Drugs Market, By End User, 2021-2029 (USD Billion)
55 Italy Age-related Macular Degeneration (AMD) Drugs Market, By Product, 2021-2029 (USD Billion)
56 Italy Age-related Macular Degeneration (AMD) Drugs Market, By T Technology Type, 2021-2029 (USD Billion)
57 Italy Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD, 2021-2029 (USD Billion)
58 italy Age-related Macular Degeneration (AMD) Drugs Market, By End User, 2021-2029 (USD Billion)
59 Spain Age-related Macular Degeneration (AMD) Drugs Market, By Product, 2021-2029 (USD Billion)
60 Spain Age-related Macular Degeneration (AMD) Drugs Market, By Molecules, 2021-2029 (USD Billion)
61 Spain Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD, 2021-2029 (USD Billion)
62 spain Age-related Macular Degeneration (AMD) Drugs Market, By End User, 2021-2029 (USD Billion)
63 Netherlands Age-related Macular Degeneration (AMD) Drugs Market, By Product, 2021-2029 (USD Billion)
64 Netherlands Age-related Macular Degeneration (AMD) Drugs Market, By Molecules, 2021-2029 (USD Billion)
65 Netherlands Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD, 2021-2029 (USD Billion)
66 Netherlands Age-related Macular Degeneration (AMD) Drugs Market, By END USER, 2021-2029 (USD Billion)
67 Rest Of Europe Age-related Macular Degeneration (AMD) Drugs Market, By Product, 2021-2029 (USD Billion)
68 Rest Of Europe Age-related Macular Degeneration (AMD) Drugs Market, By Molecules, 2021-2029 (USD Billion)
69 Rest of Europe Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD, 2021-2029 (USD Billion)
70 REST OF EUROPE Age-related Macular Degeneration (AMD) Drugs Market, By End User, 2021-2029 (USD Billion)
71 Asia Pacific Age-related Macular Degeneration (AMD) Drugs Market, By Product, 2021-2029 (USD Billion)
72 Asia Pacific Age-related Macular Degeneration (AMD) Drugs Market, By Molecules, 2021-2029 (USD Billion)
73 Asia Pacific Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD, 2021-2029 (USD Billion)
74 asia Age-related Macular Degeneration (AMD) Drugs Market, By End User, 2021-2029 (USD Billion)
75 Asia Pacific Age-related Macular Degeneration (AMD) Drugs Market, By Country, 2021-2029 (USD Billion)
76 China Age-related Macular Degeneration (AMD) Drugs Market, By Product, 2021-2029 (USD Billion)
77 China Age-related Macular Degeneration (AMD) Drugs Market, By Molecules, 2021-2029 (USD Billion)
78 China Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD, 2021-2029 (USD Billion)
79 china Age-related Macular Degeneration (AMD) Drugs Market, By End User, 2021-2029 (USD Billion)
80 India Age-related Macular Degeneration (AMD) Drugs Market, By Product, 2021-2029 (USD Billion)
81 India Age-related Macular Degeneration (AMD) Drugs Market, By Molecules, 2021-2029 (USD Billion)
82 India Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD, 2021-2029 (USD Billion)
83 india Age-related Macular Degeneration (AMD) Drugs Market, By End User, 2021-2029 (USD Billion)
84 Japan Age-related Macular Degeneration (AMD) Drugs Market, By Product, 2021-2029 (USD Billion)
85 Japan Age-related Macular Degeneration (AMD) Drugs Market, By Molecules, 2021-2029 (USD Billion)
86 Japan Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD, 2021-2029 (USD Billion)
87 japan Age-related Macular Degeneration (AMD) Drugs Market, By End User, 2021-2029 (USD Billion)
88 South Korea Age-related Macular Degeneration (AMD) Drugs Market, By Product, 2021-2029 (USD Billion)
89 South Korea Age-related Macular Degeneration (AMD) Drugs Market, By Molecules, 2021-2029 (USD Billion)
90 South Korea Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD, 2021-2029 (USD Billion)
91 south korea Age-related Macular Degeneration (AMD) Drugs Market, By End User, 2021-2029 (USD Billion)
92 Singapore Age-related Macular Degeneration (AMD) Drugs Market, By Product, 2021-2029 (USD Billion)
93 Singapore Age-related Macular Degeneration (AMD) Drugs Market, By Molecules, 2021-2029 (USD Billion)
94 Singapore Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD, 2021-2029 (USD Billion)
95 Singapore Age-related Macular Degeneration (AMD) Drugs Market, By End User, 2021-2029 (USD Billion)
96 Thailand Age-related Macular Degeneration (AMD) Drugs Market, By Product, 2021-2029 (USD Billion)
97 Thailand Age-related Macular Degeneration (AMD) Drugs Market, By Molecules, 2021-2029 (USD Billion)
98 Thailand Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD, 2021-2029 (USD Billion)
99 Thailand Age-related Macular Degeneration (AMD) Drugs Market, By End User, 2021-2029 (USD Billion)
100 MALAYSIA Age-related Macular Degeneration (AMD) Drugs Market, By Product, 2021-2029 (USD Billion)
101 MALAYSIA Age-related Macular Degeneration (AMD) Drugs Market, By Molecules, 2021-2029 (USD Billion)
102 MALAYSIA Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD, 2021-2029 (USD Billion)
103 MALAYSIA Age-related Macular Degeneration (AMD) Drugs Market, By End User, 2021-2029 (USD Billion)
104 Vietnam Age-related Macular Degeneration (AMD) Drugs Market, By Product, 2021-2029 (USD Billion)
105 Vietnam Age-related Macular Degeneration (AMD) Drugs Market, By Molecules, 2021-2029 (USD Billion)
106 Vietnam Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD, 2021-2029 (USD Billion)
107 Taiwan Age-related Macular Degeneration (AMD) Drugs Market, By Product, 2021-2029 (USD Billion)
108 Taiwan Age-related Macular Degeneration (AMD) Drugs Market, By Molecules, 2021-2029 (USD Billion)
109 Taiwan Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD, 2021-2029 (USD Billion)
110 Taiwan Age-related Macular Degeneration (AMD) Drugs Market, By End User, 2021-2029 (USD Billion)
111 REST OF APAC Age-related Macular Degeneration (AMD) Drugs Market, By Product, 2021-2029 (USD Billion)
112 REST OF APAC Age-related Macular Degeneration (AMD) Drugs Market, By Molecules, 2021-2029 (USD Billion)
113 REST OF APAC Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD, 2021-2029 (USD Billion)
114 Rest of APAC Age-related Macular Degeneration (AMD) Drugs Market, By End User, 2021-2029 (USD Billion)
115 Middle East and Africa Age-related Macular Degeneration (AMD) Drugs Market, By Product, 2021-2029 (USD Billion)
116 Middle East and Africa Age-related Macular Degeneration (AMD) Drugs Market, By Molecules, 2021-2029 (USD Billion)
117 Middle East and Africa Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD, 2021-2029 (USD Billion)
118 MIDDLE EAST AND AFRICA Age-related Macular Degeneration (AMD) Drugs Market, By End User, 2021-2029 (USD Billion)
119 Middle East and Africa Age-related Macular Degeneration (AMD) Drugs Market, By Country, 2021-2029 (USD Billion)
120 Saudi Arabia Age-related Macular Degeneration (AMD) Drugs Market, By Product, 2021-2029 (USD Billion)
121 Saudi Arabia Age-related Macular Degeneration (AMD) Drugs Market, By Molecules, 2021-2029 (USD Billion)
122 Saudi Arabia Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD, 2021-2029 (USD Billion)
123 saudi arabia Age-related Macular Degeneration (AMD) Drugs Market, By End User, 2021-2029 (USD Billion)
124 UAE Age-related Macular Degeneration (AMD) Drugs Market, By Product, 2021-2029 (USD Billion)
125 UAE Age-related Macular Degeneration (AMD) Drugs Market, By Molecules, 2021-2029 (USD Billion)
126 UAE Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD, 2021-2029 (USD Billion)
127 uae Age-related Macular Degeneration (AMD) Drugs Market, By End User, 2021-2029 (USD Billion)
128 Israel Age-related Macular Degeneration (AMD) Drugs Market, By Product, 2021-2029 (USD Billion)
129 Israel Age-related Macular Degeneration (AMD) Drugs Market, By Molecules, 2021-2029 (USD Billion)
130 Israel Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD, 2021-2029 (USD Billion)
131 Israel Age-related Macular Degeneration (AMD) Drugs Market, By End User, 2021-2029 (USD Billion)
132 South Africa Age-related Macular Degeneration (AMD) Drugs Market, By Product, 2021-2029 (USD Billion)
133 South Africa Age-related Macular Degeneration (AMD) Drugs Market, By Molecules, 2021-2029 (USD Billion)
134 South Africa Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD, 2021-2029 (USD Billion)
135 South Africa Age-related Macular Degeneration (AMD) Drugs Market, By End User, 2021-2029 (USD Billion)
136 REST OF MIDDLE EAST AND AFRICA Age-related Macular Degeneration (AMD) Drugs Market, By Product, 2021-2029 (USD Billion)
137 REST OF MIDDLE EAST AND AFRICA Age-related Macular Degeneration (AMD) Drugs Market, By Molecules, 2021-2029 (USD Billion)
138 REST OF MIDDLE EAST AND AFRICA Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD, 2021-2029 (USD Billion)
139 REST OF MIDDLE EAST AND AFRICA Age-related Macular Degeneration (AMD) Drugs Market, By End User, 2021-2029 (USD Billion)
140 Central & South America Age-related Macular Degeneration (AMD) Drugs Market, By Product, 2021-2029 (USD Billion)
141 Central & South America Age-related Macular Degeneration (AMD) Drugs Market, By Molecules, 2021-2029 (USD Billion)
142 Central & South America Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD, 2021-2029 (USD Billion)
143 CENTRAL & SOUTH AMERICA Age-related Macular Degeneration (AMD) Drugs Market, By End User, 2021-2029 (USD Billion)
144 Central & South America Age-related Macular Degeneration (AMD) Drugs Market, By Country, 2021-2029 (USD Billion)
145 Brazil Age-related Macular Degeneration (AMD) Drugs Market, By Product, 2021-2029 (USD Billion)
146 Brazil Age-related Macular Degeneration (AMD) Drugs Market, By Molecules, 2021-2029 (USD Billion)
147 Brazil Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD, 2021-2029 (USD Billion)
148 brazil Age-related Macular Degeneration (AMD) Drugs Market, By End User, 2021-2029 (USD Billion)
149 Chile Age-related Macular Degeneration (AMD) Drugs Market, By Product, 2021-2029 (USD Billion)
150 Chile Age-related Macular Degeneration (AMD) Drugs Market, By Molecules, 2021-2029 (USD Billion)
151 Chile Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD, 2021-2029 (USD Billion)
152 Chile Age-related Macular Degeneration (AMD) Drugs Market, By End User, 2021-2029 (USD Billion)
153 Argentina Age-related Macular Degeneration (AMD) Drugs Market, By Product, 2021-2029 (USD Billion)
154 Argentina Age-related Macular Degeneration (AMD) Drugs Market, By Molecules, 2021-2029 (USD Billion)
155 Argentina Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD, 2021-2029 (USD Billion)
156 Argentina Age-related Macular Degeneration (AMD) Drugs Market, By End User, 2021-2029 (USD Billion)
157 REST OF CENTRAL AND SOUTH AMERICA Age-related Macular Degeneration (AMD) Drugs Market, By Product, 2021-2029 (USD Billion)
158 REST OF CENTRAL AND SOUTH AMERICA Age-related Macular Degeneration (AMD) Drugs Market, By Molecules, 2021-2029 (USD Billion)
159 REST OF CENTRAL AND SOUTH AMERICA Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD, 2021-2029 (USD Billion)
160 REST OF CENTRAL AND SOUTH AMERICA Age-related Macular Degeneration (AMD) Drugs Market, By End User, 2021-2029 (USD Billion)
161 Regeneron Pharmaceuticals Inc.: Products & Services Offering
162 Bayer AG: Products & Services Offering
163 F. Hoffmann-La Roche AG: Products & Services Offering
164 Novartis AG: Products & Services Offering
165 Apellis Pharmaceuticals, Inc.: Products & Services Offering
166 COHERUS BIOSCIENCES, INC.: Products & Services Offering
167 Astellas Pharma Inc.: Products & Services Offering
168 Biogen: Products & Services Offering
169 STADA Arzneimittel AG, Inc: Products & Services Offering
170 Formycon AG: Products & Services Offering
171 Other Companies: Products & Services Offering
LIST OF FIGURES
1 Global Age-related Macular Degeneration (AMD) Drugs Market Overview
2 Global Age-related Macular Degeneration (AMD) Drugs Market Value From 2021-2029 (USD Billion)
3 Global Age-related Macular Degeneration (AMD) Drugs Market Share, By Product (2023)
4 Global Age-related Macular Degeneration (AMD) Drugs Market Share, By Molecules (2023)
5 Global Age-related Macular Degeneration (AMD) Drugs Market Share, By Type of AMD (2023)
6 Global Age-related Macular Degeneration (AMD) Drugs Market Share, By End User (2023)
7 Global Age-related Macular Degeneration (AMD) Drugs Market, By Region (Asia Pacific Market)
8 Technological Trends In Global Age-related Macular Degeneration (AMD) Drugs Market
9 Four Quadrant Competitor Positioning Matrix
10 Impact Of Macro & Micro Indicators On The Market
11 Impact Of Key Drivers On The Global Age-related Macular Degeneration (AMD) Drugs Market
12 Impact Of Challenges On The Global Age-related Macular Degeneration (AMD) Drugs Market
13 Porter’s Five Forces Analysis
14 Global Age-related Macular Degeneration (AMD) Drugs Market: By Product Scope Key Takeaways
15 Global Age-related Macular Degeneration (AMD) Drugs Market, By Product Segment: Revenue Growth Analysis
16 Lucentis Market, By Region, 2021-2029 (USD Billion)
17 Eylea & Eylea HD Market, By Region, 2021-2029 (USD Billion)
18 Vabysmo Market, By Region, 2021-2029 (USD Billion)
19 Syfovre Market, By Region, 2021-2029 (USD Billion)
20 Others Market, By Region, 2021-2029 (USD Billion)
21 Global Age-related Macular Degeneration (AMD) Drugs Market: By Molecules Scope Key Takeaways
22 Global Age-related Macular Degeneration (AMD) Drugs Market, By Molecules Segment: Revenue Growth Analysis
23 Ranibizumab Market, By Region, 2021-2029 (USD Billion)
24 Aflibercept Market, By Region, 2021-2029 (USD Billion)
25 Faricimab Market, By Region, 2021-2029 (USD Billion)
26 Pegcetoplan Market, By Region, 2021-2029 (USD Billion)
27 Others Market, By Region, 2021-2029 (USD Billion)
28 Global Age-related Macular Degeneration (AMD) Drugs Market: By Type of AMD Scope Key Takeaways
29 Global Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD Segment: Revenue Growth Analysis
30 Wet AMD Market, By Region, 2021-2029 (USD Billion)
31 Dry AMD Market, By Region, 2021-2029 (USD Billion)
32 Global Age-related Macular Degeneration (AMD) Drugs Market: By End User Scope Key Takeaways
33 Global Age-related Macular Degeneration (AMD) Drugs Market, By End User Segment: Revenue Growth Analysis
34 Specialty Centers Market, By Region, 2021-2029 (USD Billion)
35 Long-term Care Facilities Market, By Region, 2021-2029 (USD Billion)
36 Hospitals Market, By Region, 2021-2029 (USD Billion)
37 Regional Segment: Revenue Growth Analysis
38 Global Age-related Macular Degeneration (AMD) Drugs Market: Regional Analysis
39 North America Age-related Macular Degeneration (AMD) Drugs Market Overview
40 North America Age-related Macular Degeneration (AMD) Drugs Market, By Product
41 North America Age-related Macular Degeneration (AMD) Drugs Market, By Molecules
42 North America Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD
43 North America Age-related Macular Degeneration (AMD) Drugs Market, By End User
44 North America Age-related Macular Degeneration (AMD) Drugs Market, By Country
45 U.S. Age-related Macular Degeneration (AMD) Drugs Market, By Product
46 U.S. Age-related Macular Degeneration (AMD) Drugs Market, By Molecules
47 U.S. Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD
48 U.S. Age-related Macular Degeneration (AMD) Drugs Market, By End User
49 Canada Age-related Macular Degeneration (AMD) Drugs Market, By Product
50 Canada Age-related Macular Degeneration (AMD) Drugs Market, By Molecules
51 Canada Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD
52 Canada Age-related Macular Degeneration (AMD) Drugs Market, By End User
53 Mexico Age-related Macular Degeneration (AMD) Drugs Market, By Product
54 Mexico Age-related Macular Degeneration (AMD) Drugs Market, By Molecules
55 Mexico Age-related Macular Degeneration (AMD) Drugs Market, By Type of AMD
56 Mexico Age-related Macular Degeneration (AMD) Drugs Market, By End User
57 Four Quadrant Positioning Matrix
58 Company Market Share Analysis
59 Regeneron Pharmaceuticals Inc.: Company Snapshot
60 Regeneron Pharmaceuticals Inc.: SWOT Analysis
61 Regeneron Pharmaceuticals Inc.: Geographic Presence
62 Bayer AG: Company Snapshot
63 Bayer AG: SWOT Analysis
64 Bayer AG: Geographic Presence
65 F. Hoffmann-La Roche AG: Company Snapshot
66 F. Hoffmann-La Roche AG: SWOT Analysis
67 F. Hoffmann-La Roche AG: Geographic Presence
68 Novartis AG: Company Snapshot
69 Novartis AG: Swot Analysis
70 Novartis AG: Geographic Presence
71 Apellis Pharmaceuticals, Inc.: Company Snapshot
72 Apellis Pharmaceuticals, Inc.: SWOT Analysis
73 Apellis Pharmaceuticals, Inc.: Geographic Presence
74 COHERUS BIOSCIENCES, INC.: Company Snapshot
75 COHERUS BIOSCIENCES, INC.: SWOT Analysis
76 COHERUS BIOSCIENCES, INC.: Geographic Presence
77 Astellas Pharma Inc. : Company Snapshot
78 Astellas Pharma Inc. : SWOT Analysis
79 Astellas Pharma Inc. : Geographic Presence
80 Biogen: Company Snapshot
81 Biogen: SWOT Analysis
82 Biogen: Geographic Presence
83 STADA Arzneimittel AG, Inc.: Company Snapshot
84 STADA Arzneimittel AG, Inc.: SWOT Analysis
85 STADA Arzneimittel AG, Inc.: Geographic Presence
86 Formycon AG: Company Snapshot
87 Formycon AG: SWOT Analysis
88 Formycon AG: Geographic Presence
89 Other Companies: Company Snapshot
90 Other Companies: SWOT Analysis
91 Other Companies: Geographic Presence
The Global Age-related Macular Degeneration (AMD) Drugs Market has been studied from the year 2019 till 2029. However, the CAGR provided in the report is from the year 2024 to 2029. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Age-related Macular Degeneration (AMD) Drugs Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.
Frequently Asked Questions
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
Or view our licence options:
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
OUR CLIENTS
